OBJECTIVES: The prodynorphin gene (PDYN) promoter has a repeat polymorphism that is functionally important in association with substance abuse. We examined this polymorphism for association in our sample of 168 opioid-dependent patients and 122 ethnically and geographically matched controls. METHODS: Patients were selected from university-affiliated residential and non-residential addiction treatment programs in the Philadelphia area. A sample of blood was drawn from consenting individuals and genomic DNA was isolated. Polymerase chain reaction amplification of the PDYN promoter was performed and various genotypes were determined on the basis of differing sizes of the polymerase chain reaction products. The genotype and allele data were analyzed by Fisher's exact test. RESULT: A significant difference in genotype (P<0.0006) and allele (P<10) frequencies was found between the African American and European American populations. We did not detect any significant difference in genotype or allele frequencies between the patients and controls within the European American ethnic group. However, we detected a weak association (P=0.013) when we compared allele frequencies of patients and controls in the African American population. CONCLUSIONS: These data suggest that the PDYN repeat polymorphism should be studied in additional opioid-dependent populations.
OBJECTIVES: The prodynorphin gene (PDYN) promoter has a repeat polymorphism that is functionally important in association with substance abuse. We examined this polymorphism for association in our sample of 168 opioid-dependent patients and 122 ethnically and geographically matched controls. METHODS:Patients were selected from university-affiliated residential and non-residential addiction treatment programs in the Philadelphia area. A sample of blood was drawn from consenting individuals and genomic DNA was isolated. Polymerase chain reaction amplification of the PDYN promoter was performed and various genotypes were determined on the basis of differing sizes of the polymerase chain reaction products. The genotype and allele data were analyzed by Fisher's exact test. RESULT: A significant difference in genotype (P<0.0006) and allele (P<10) frequencies was found between the African American and European American populations. We did not detect any significant difference in genotype or allele frequencies between the patients and controls within the European American ethnic group. However, we detected a weak association (P=0.013) when we compared allele frequencies of patients and controls in the African American population. CONCLUSIONS: These data suggest that the PDYN repeat polymorphism should be studied in additional opioid-dependent populations.
Authors: Vadim Yuferov; Matthew Randesi; Eduardo R Butelman; Wim van den Brink; Peter Blanken; Jan M van Ree; Jürg Ott; Mary Jeanne Kreek Journal: Neurosci Lett Date: 2019-03-29 Impact factor: 3.046
Authors: Elliot C Nelson; Michael T Lynskey; Andrew C Heath; Naomi Wray; Arpana Agrawal; Fiona L Shand; Anjali K Henders; Leanne Wallace; Alexandre A Todorov; Andrew J Schrage; Nancy L Saccone; Pamela A F Madden; Louisa Degenhardt; Nicholas G Martin; Grant W Montgomery Journal: JAMA Psychiatry Date: 2013-03 Impact factor: 21.596
Authors: Andrej Nikoshkov; Katarina Drakenberg; Xinyu Wang; Monika Cs Horvath; Eva Keller; Yasmin L Hurd Journal: Proc Natl Acad Sci U S A Date: 2008-01-09 Impact factor: 11.205
Authors: Heike Kölsch; Michael Wagner; Andras Bilkei-Gorzó; Mohammad Reza Toliat; Michael Pentzek; Angela Fuchs; Hanna Kaduszkiewicz; Hendrik van den Bussche; Steffi G Riedel-Heller; Matthias C Angermeyer; Siegfried Weyerer; Jochen Werle; Horst Bickel; Edelgard Mösch; Birgitt Wiese; Moritz Daerr; Frank Jessen; Wolfgang Maier; Martin Dichgans Journal: J Neural Transm (Vienna) Date: 2009-05-26 Impact factor: 3.575